Zsírmáj (MASLD/MASH): vizsgálatok itt: Hongkong

In Hongkong 14 Also abroad 367

14 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

3. fázisTaking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Hong Kong
Életkor
18 év and over
People
1800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
3. fázisTaking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Hong Kong
Életkor
18 év and over
People
1590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
3. fázisTaking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Hong Kong, Shatin
Életkor
18 év to 80 év
People
1350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Where
Hong Kong, Shatin
Életkor
18 év to 75 év
People
1800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00
3. fázisTaking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Hksar, Shatin, Tuenmen
Életkor
18 év and over
People
4500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
3. fázisTaking people
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Where
Pokfulam
Életkor
18 év to 75 év
People
1250 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00
No phaseTaking people
Duodenal pulsENDO as an Early Treatment for Type 2 DM
Where
Shatin
Életkor
18 év to 60 év
People
40
Run by
Chinese University of Hong Kong
See details and how to joinNCT07376486
No phaseTaking people
Duodenal pulsENDO for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease
Where
Shatin
Életkor
18 év to 70 év
People
40
Run by
Chinese University of Hong Kong
See details and how to joinNCT07390422
No phaseTaking people
Longitudinal Observational Study Of Chinese With NAFLD/NASH
Where
Hong Kong
Életkor
18 év and over
People
20 000
Run by
Humanity and Health Research Centre
See details and how to joinNCT03151473
3. fázisTaking people
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Where
Pokfulam
Életkor
18 év to 75 év
People
1200 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221227
No phaseTaking people
Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity
Where
Hong Kong
Életkor
18 év and over
People
200
Run by
Chinese University of Hong Kong
See details and how to joinNCT07662356
No phaseTaking people
Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention
Where
Hong Kong
Életkor
18 év to 65 év
People
80
Run by
Chinese University of Hong Kong
See details and how to joinNCT03875625
No phaseTaking people
Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter
Where
Hong Kong
Életkor
18 év to 65 év
People
150
Run by
Chinese University of Hong Kong
See details and how to joinNCT06203548
No phaseTaking people
Vigorous- Versus Moderate-intensity Exercise to Reduce Liver Fat in Adults With Obesity and NAFLD
Where
Hong Kong
Életkor
18 év to 69 év
People
330
Run by
The University of Hong Kong
See details and how to joinNCT06124456